Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 2/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27568637 | 0.85 | HTR6 (0.47) | HTR6HTR1ADRD2HTR2A | |
| SCHEMBL1537845 | 0.81 | HTR6 (0.75) | HTR6HTR1ADRD2HTR2ABCHE | |
| SCHEMBL5705149 | 0.80 | HTR6 (0.65) | HTR6GPR119 | |
| SCHEMBL2798747 | 0.79 | KIT (0.49) | HTR6PIK3CAGPR119 | |
| SCHEMBL2230089 | 0.79 | KDM4E (0.48) | HTR6GPR119TGM2F13A1BACE1 | |
| SCHEMBL5704771 | 0.79 | HTR6 (0.67) | HTR6GPR119 | |
| Tert-Butyl Formate SCHEMBL27568639 | 0.79 | HTR6 (0.58) | HTR6 | |
| SCHEMBL1136424 | 0.78 | HTR6 (0.71) | HTR6 | |
| SCHEMBL4783125 | 0.77 | CCR8 (0.52) | HTR6GPR119TGFBR1BCHE | |
| SCHEMBL5202415 | 0.77 | HTR6 (0.52) | HTR6HTR1ADRD2HTR2APIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401812-B1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2006-06-28 | — | — | EP | disclosed |
| US-6790848-B2 | TREATING CENTRAL NERVOUS SYSTEM OR GASTROINTESTINAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-09-14 | — | — | US | disclosed |
| EP-1401812-A1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102774-A1 | 4-PIPERAZINYLINDOLE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045527-A1 | 4-piperazinylindole derivatives with 5-HT6 receptor affinity | HTR6, HTR5A, HTR3A | HTR6 1/4885HTR1A 6/4885DRD2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.